top of page

BIO-Europe: Germany based HepaRegeniX is targeting MKK4 to spur regeneration in diseased livers. This year the company has published clinical data and raised a series C

  • Nov 4, 2024
  • 1 min read

CEO Elias Papatheodorou describes the unmet need in liver disease and the rationale for MKK4, a target HepaRegeniX is focused on and is based on work by Professor Lars Zender University Hospital, Tübingen, Germany.



Brought to you by



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

​

​Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page